Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of repaglinide and metformin combination therapy in Chinese subjects with type 2 diabetes inadequately controlled with OAD (oral anti-diabetic drugs).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Metformin; Repaglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes for at least 12 weeks

• HbA1c: 8.0-10.0%

• Current treatment with OAD on monotheray or OAD on combination therapy

• Body mass index (BMI): 21.0-35.0 kg/m2

Exclusion Criteria:

• Known or suspected allergy to trial product(s) or related products

• Recurrent major hypoglycaemia as judged by the Investigator

• Uncontrolled hypertension

• Any other significant condition or concomitant disease such as endocrine, cardiac, neurological, malignant or other pancreatic disease as judged by the Investigator